Bob Bradway, Amgen CEO (Stephen Lam/Reuters)
Amgen launches the first US Humira biosimilar at two different list prices
The bizarre dynamics of the US prescription drug market were on full display once again this morning as Amgen announced that it would launch the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
